Výsledky vyhledávání - "Marcus Schonemann"

Discovery of azaspirocyclic 1H-3,4,5-Trisubstitued pyrazoles as novel G2019S-LRRK2 selective kinase inhibitors

Autor: Robert K. Leśniak, R. Jeremy Nichols, Marcus Schonemann, Jing Zhao, Chandresh R. Gajera, Grace Lam, Khanh C. Nguyen, J. William Langston, Mark Smith, Thomas J. Montine

Publikováno v: European journal of medicinal chemistry. 242

Mutations in the Leucine Rich Repeat Protein Kinase 2 gene (LRRK2) are genetic predispositions for Parkinson's Disease, of which the G2019S (GS) missense mutation is the most common. GS-LRRK2 has a hyperactive kinase, and although numerous drug disco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7afa298b16b52ef5c74636de19c67d88
https://pubmed.ncbi.nlm.nih.gov/36049274

Zobrazit plný text záznamu

Discovery of 1H-Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors

Autor: Robert K. Leśniak, R. Jeremy Nichols, Marcus Schonemann, Jing Zhao, Chandresh R. Gajera, Grace Lam, Khanh C. Nguyen, J. William Langston, Mark Smith, Thomas J. Montine

Publikováno v: ACS Med Chem Lett

[Image: see text] G2019S (GS) is the most prevalent mutation in the leucine rich repeat protein kinase 2 gene (LRRK2), a genetic predisposition that is common for Parkinson’s disease, as well as for some forms of cancer, and is a shared risk allele

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75edb524222030a37a7cce5cca6241aa
https://europepmc.org/articles/PMC9190033/

Zobrazit plný text záznamu

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy

Autor: Robert K. Leśniak, R. Jeremy Nichols, Marcus Schonemann, Jing Zhao, Chandresh R. Gajera, William L. Fitch, Grace Lam, Khanh C. Nguyen, Mark Smith, Thomas J. Montine

Publikováno v: European journal of medicinal chemistry. 229

Mutations in the Leucine Rich Repeat Protein Kinase 2 gene (LRRK2) are the most common genetic causes of Parkinson's Disease (PD). The G2019S mutation is the most common inherited LRRK2 mutation, occurs in the kinase domain, and results in increased

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::643144c274ffd8f416b88301b9674c66
https://pubmed.ncbi.nlm.nih.gov/34992038

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání